There is currently no effective treatment for dengue and severe dengue that cause significant morbidity and mortality worldwide. We are working with partners to plan new clinical trials that address this pressing issue
To date, dengue research has been based on heterogeneous outcomes measures which have prevented the comparison of results across different studies and limited the impact of the evidence generated.
By incorporating input from a broad range of stakeholders, including patient groups, health professionals and researchers, a core outcome set will ensure that research is both relevant and patient-centred, resulting in better informed clinical and policy decisions on a global scale. The core outcome set will also anchor the development of target product profiles for new therapeutic agents to treat Dengue.
The Den-core team was formed in 2023 to develop a Core Outcome Set (COS) for use in dengue research with input from patient representatives, health professionals, psychologists, researchers, methodologists, epidemiologists, journal editors, industry, policy makers, and regulators.
Together, this range of stakeholders will develop a consistent framework for outcome selection and reporting. The COS will contribute to improved research quality, data comparability, and evidence synthesis, ultimately facilitating the development of effective interventions and evidence-based clinical practice.
